You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 17, 2024

CLINICAL TRIALS PROFILE FOR KW-6356

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for KW-6356

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02939391 ↗	A Study of KW-6356 in Subjects With Early Parkinson's Disease	Completed	Kyowa Hakko Kirin Company, Limited	Phase 2	The primary objective is to evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in the MDS-UPDRS part III score between KW-6356 and placebo in subjects with early Parkinson's disease in Japan.
NCT02939391 ↗	A Study of KW-6356 in Subjects With Early Parkinson's Disease	Completed	Kyowa Kirin Co., Ltd.	Phase 2	The primary objective is to evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in the MDS-UPDRS part III score between KW-6356 and placebo in subjects with early Parkinson's disease in Japan.
NCT03703570 ↗	A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations	Completed	Kyowa Hakko Kirin Co., Ltd	Phase 2	The primary objective of this study is to determine the recommended dose and evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in Movement disorder society-unified Parkinson's disease rating scale(MDS-UPDRS) partIII score between KW-6356 and placebo in patients with Parkinson's disease on treatment with Levodopa-containing preparations as an adjunctive therapy.
NCT03703570 ↗	A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations	Completed	Kyowa Kirin Co., Ltd.	Phase 2	The primary objective of this study is to determine the recommended dose and evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in Movement disorder society-unified Parkinson's disease rating scale(MDS-UPDRS) partIII score between KW-6356 and placebo in patients with Parkinson's disease on treatment with Levodopa-containing preparations as an adjunctive therapy.
NCT03830528 ↗	A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects	Completed	Kyowa Hakko Kirin Co., Ltd	Phase 1	Phase I study to assess the safety, tolerability and pharmacokinetics of single and multiple doses of KW-6356 in healthy volunteers
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for KW-6356

Condition Name

Chart
Table

Condition Name for
Intervention	Trials
Parkinson's Disease	6
Healthy Male Subjects	1
Hepatic Impairment	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for
Intervention	Trials
Parkinson Disease	6
Liver Diseases	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for KW-6356

Trials by Country

Map
Table

Trials by Country for
Location	Trials
Japan	12
United States	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for
Location	Trials
Texas	1
Florida	1
Wisconsin	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for KW-6356

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 2	2
Phase 1	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for KW-6356

Sponsor Name

Chart
Table

Sponsor Name for
Sponsor	Trials
Kyowa Kirin Co., Ltd.	6
Kyowa Hakko Kirin Co., Ltd	3
Kyowa Kirin Pharmaceutical Development, Inc.	2
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for
Sponsor	Trials
Industry	13
Other	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.